Factor XIs: Are they the Knockout Round in Next Phase Antithrombotic Therapies?-New in the Ring: Factor XI Inhibitors

Video Transcription

Video Summary

Dr. Kristen Campbell introduced the latest developments in anticoagulation, highlighting new agents targeting Factor XI inhibitors. Unlike current anticoagulants that mostly interact with thrombin or Factor Xa, these new agents, such as antisense oligonucleotides, monoclonal antibodies, and small molecules, specifically target Factor XI, which is crucial for thrombus growth but not vital for hemostasis. This approach may reduce pathological clot formation while minimizing bleeding risks. These agents have diverse mechanisms, including oral options, and offer benefits like minimal renal elimination and few drug interactions, potentially expanding anticoagulation therapies for challenging patient populations.

Keywords

Factor XI inhibitors

anticoagulation

antisense oligonucleotides

monoclonal antibodies

thrombus growth